MRx-4DP0004 is a probiotic bacteria indicated in the treatment of diarrhea. MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria.
- Mechanism
- Curator reviewed
MRx-4DP0004 is an immunomodulatory therapy with anti-viral activity that simultaneously downregulates molecules associated with hyper-inflammatory responses. It reduces neutrophilic and eosinophilic infiltration in the lungs, in addition to a reduction in peribronchiolar and perivascular immunopathology without the side effects associated with immunosuppressants. A study of MRx-4DP0004 also demonstrated specifics of the biotherapeutic increasing lung D4+CD44+ cells and CD4+FoxP3+ cells, decreasing activated CD11b+ dendritic cells, and reducing pro-inflammatory cytokines and chemokines involved in neutrophil migration. MRx-4DP0004 is currently being investigated for severe asthma management, however, the specific mechanism of action is currently unknown.
- Code names
- MRx-4DP0004
What you can answer from here — as of October 30, 2025
Which companies are running trials of MRx-4DP0004, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account